Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
PHASE1CompletedINTERVENTIONAL
Enrollment
7
Participants
Timeline
Start Date
November 5, 2019
Primary Completion Date
February 14, 2024
Study Completion Date
February 14, 2024
Conditions
Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRichter SyndromeSmall Lymphocytic LymphomaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
DRUG
Duvelisib
Given PO
BIOLOGICAL
Nivolumab
Given IV
Trial Locations (1)
43210
Ohio State University Comprehensive Cancer Center, Columbus